In patients with the postural instability gait difficulty (PIGD) variant of Parkinson’s disease, can levodopa/carbidopa (Syndopa) and amantadine be used together?

Yes, Syndopa (levodopa/carbidopa) and amantadine can and should be used together in PIGD variant Parkinson's disease

The combination of levodopa/carbidopa with amantadine is explicitly indicated and beneficial for Parkinson's disease patients, including those with the PIGD subtype. This combination provides additive therapeutic benefit beyond either drug alone 1, 2.

Rationale for Combination Therapy

FDA-Approved Indication

Amantadine is FDA-approved specifically for use in Parkinson's disease, both as monotherapy and in combination with levodopa 1. The drug label explicitly states that "when amantadine and levodopa are initiated concurrently, the patient can exhibit rapid therapeutic benefits" and that "when amantadine is added to optimal well-tolerated doses of levodopa, additional benefit may result" 1.

Evidence Supporting Combination Use

The combination demonstrates superior efficacy compared to single-drug therapy:

• 92% improvement in symptom scores and 95% improvement in activity impairment scores when amantadine was added to levodopa/carbidopa therapy 2
• Between 64-100% of patients improved when the second drug was added to single-drug therapy 3
• The combination allows for lower levodopa doses (70 mg less daily increase needed), which is particularly important for long-term management 4

Special Considerations for PIGD Subtype

The PIGD Challenge

PIGD patients present a therapeutic challenge because:

• Levodopa alone may not improve and can actually worsen gait stability in PIGD patients, particularly mediolateral and vertical pelvis stability 5
• PIGD patients show worse head and trunk stability that persists even in the "on" medication state 5
• This subtype is associated with more severe disease, higher levodopa requirements, and worse prognosis 6

Why Amantadine Matters More in PIGD

Recent evidence suggests amantadine may offer specific benefits for PIGD-related symptoms:

• Significant positive effects on freezing of gait were observed with amantadine 4
• Amantadine reduces fatigue and improves quality of life beyond motor symptom control 4
• The drug may delay dyskinesia onset by 50% over 18 months, allowing for more aggressive levodopa dosing when needed 4, 7

Practical Dosing Algorithm

Starting Regimen

1. Continue current Syndopa dose (levodopa/carbidopa)
2. Add amantadine 100 mg once daily for patients with serious medical illnesses or those on high-dose antiparkinson drugs 1
3. After 1-2 weeks, increase to 100 mg twice daily (200 mg/day total) if tolerated 1

Dose Optimization

• If response remains suboptimal at 200 mg/day, increase to 300 mg/day in divided doses with close supervision 1
• Maximum dose: 400 mg/day in divided doses for selected patients under close monitoring 1

Critical Dosing Adjustments

Renal impairment requires mandatory dose reduction 1:

• CrCl 30-50 mL/min: 200 mg on day 1, then 100 mg daily
• CrCl 15-29 mL/min: 200 mg on day 1, then 100 mg every other day
• CrCl <15 mL/min: 200 mg every 7 days
• Patients ≥65 years require dose reduction due to age-related renal decline 1

Important Safety Monitoring

Common Pitfalls to Avoid

1. Do not abruptly discontinue amantadine - withdrawal effects are as serious as with other antiparkinson medications and require gradual tapering 8
2. Monitor for impulse control disorders - gambling urges, hypersexuality, compulsive spending can occur with any dopaminergic therapy including amantadine 1
3. Watch for anticholinergic effects - blurred vision, confusion, urinary retention, particularly when combined with other anticholinergics 1
4. Screen for melanoma regularly - all PD patients have 2-6 fold increased melanoma risk 1

Side Effects More Common in Specific Populations

• Edema and livedo reticularis occur twice as often in women 8
• Confusion and hallucinations appear sooner at 300 mg/day but ultimate incidence is similar to 200 mg/day 8
• Orthostatic hypotension risk increases - advise patients to rise slowly from sitting/lying 1

When to Reassess

Loss of Efficacy Pattern

Patients may experience "fall-off" of effectiveness after several months 1. When this occurs:

1. Increase amantadine to 300 mg daily in divided doses
2. Alternatively, temporarily discontinue for several weeks, then reinitiate - this may restore benefit 1
3. Consider adding other antiparkinson drugs if combination therapy becomes insufficient 1

Expected Timeline

• Onset of action: 48 hours for amantadine 1
• Greatest effect in first month, with diminishing returns after 6 months for some patients 8
• However, long-term studies show sustained benefit in many patients over 21+ months 3

The combination is safe, FDA-approved, and provides measurable clinical benefit that exceeds either drug alone, making it a rational therapeutic strategy for PIGD Parkinson's disease.